Orexin Receptor Agonist Compounds for Sleep-Wake Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurological and psychiatric disorders related to orexin receptors lack effective agonists that can modulate these receptors to address sleep disorders, feeding behavior, arousal, emotion, energy homeostasis, and memory issues.
Innovation Solution
Development of 3-heteroaryl pyrrolidine and piperidine compounds that act as orexin receptor agonists, potentially treating or preventing disorders associated with these receptors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for neurological and psychiatric disorders are used, then existing therapeutic approaches are maintained, but effective agonists that can modulate orexin receptors are lacking
Solution Approach 1:
The patent applies parameter changes by developing novel chemical compounds with specific molecular structures (3-heteroaryl pyrrolidine and piperidine compounds) that have different pharmacological properties compared to existing treatments. These compounds are designed to specifically target orexin receptors with agonist activity, changing the chemical and biological parameters of the therapeutic approach to achieve reliable modulation of sleep-wake regulation, feeding behavior, and other orexin-mediated functions.
2Reliability
If novel 3-heteroaryl pyrrolidine and piperidine compounds are developed as orexin receptor agonists, then therapeutic benefits for neurological and psychiatric disorders are achieved, but the complexity of drug development and characterization increases
Solution Approach 1:
The patent applies segmentation by dividing the drug development process into distinct stages: compound synthesis, in vitro receptor binding assays, in vivo pharmacological studies, and preclinical toxicology. This segmentation allows systematic evaluation of each novel compound's properties and effects, managing the overall complexity through structured, modular development phases while achieving reliable therapeutic benefits.
Solution Approach 2:
The patent uses intermediary approaches by employing specific assay systems and model organisms to evaluate the novel compounds before human application. In vitro binding assays using purified orexin receptors and in vivo studies in animal models serve as intermediaries to predict human therapeutic responses, reducing the direct complexity of developing and testing these complex compounds.
3Reliability
If orexin receptor agonists are used to treat sleep disorders and other conditions, then effective modulation of sleep-wake regulation and other functions is achieved, but potential side effects and safety concerns may arise
Solution Approach 1:
The patent applies preliminary anti-action by conducting comprehensive preclinical safety evaluations and toxicology studies before potential human use of the orexin receptor agonists. These preliminary studies identify and address potential harmful effects in advance, establishing safety profiles and dosing ranges that minimize side effects while maintaining effective functional modulation of sleep-wake regulation, feeding behavior, and other orexin-mediated functions.
Data Source
AI summary
The present invention is directed to 3-heteroaryl pyrrolidine and piperidine compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.